Abstract
BackgroundPlasmacytoma variant translocation 1 (PVT1) has recently been reported to be aberrantly expressed and serves as a prognostic biomarker in many types of cancers. However, its prognostic significance remains controversial. Here, we conducted a meta-analysis to investigate the prognostic value of PVT1 expression in cancers.ResultsA total of 2109 patients from 20 studies were included. The results showed that elevated PVT1 expression predicted a poor outcome for overall survival (OS) in nine types of cancers (HR = 1.40, 95% CI: 1.21–1.59). Subgroup analysis indicated that there was a significant association between PVT1 overexpression and poor OS of patients with gastric cancer, gynecology cancer and lung cancer. Furthermore, we also found a negative significant relationship between PVT1 expression and disease-free survival (HR = 1.83, 95% CI: 1.39–2.27), progression-free survival (HR = 1.63, 95% CI: 1.34–1.93) and recurrence-free survival (HR = 1.74, 95% CI: 1.01–2.47). In addition, the level of PVT1 expression was positively related to tumor size, TNM stage, lymph node metastasis and distant metastases.Materials and MethodsA systematic search was performed through the PubMed, EMBASE, Web of Science, Ovid and Cochrane library databases for eligible studies on prognostic value of PVT1 in cancers from inception up to June, 2017. The pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the association between PVT1 expression and clinical outcomes.ConclusionsPVT1 expression positively related to tumor size, TNM stages, lymph node metastasis and distant metastases, and served as a prognostic biomarker in different types of cancers.
Highlights
Long noncoding RNAs are evolutionarily conserved non-protein coding RNAs that are longer than 200 nucleotides in length [1]
The results showed that elevated Plasmacytoma variant translocation 1 (PVT1) expression predicted a poor outcome for overall survival (OS) in nine types of cancers (HR = 1.40, 95% confidence intervals (CIs): 1.21–1.59)
We found a negative significant relationship between PVT1 expression and disease-free survival (HR = 1.83, 95% CI: 1.39–2.27), progressionfree survival (HR = 1.63, 95% CI: 1.34–1.93) and recurrence-free survival (HR = 1.74, 95% CI: 1.01–2.47)
Summary
Long noncoding RNAs (lncRNAs) are evolutionarily conserved non-protein coding RNAs that are longer than 200 nucleotides in length [1]. It has been reported that lncRNAs regulate gene expression through diverse molecular processes, including transcriptional and posttranscriptional processing, chromatin modification and epigenetics, genomic imprinting, protein activity modulation and protein localization [2]. Emerging evidence has indicated that dysregulation of lncRNAs is often associated with a variety of human diseases including cancer [3, 4]. LncRNAs could play important regulators in various cancer-related processes such as modulation of apoptosis and proliferation, drug resistance and the process of epithelial-mesenchymal transition [5]. The role of most lncRNAs in cancer progression still remains unclear. Plasmacytoma variant translocation 1 (PVT1) has recently been reported to be aberrantly expressed and serves as a prognostic biomarker in many types of cancers. We conducted a meta-analysis to investigate the prognostic value of PVT1 expression in cancers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
